Loading...
The 2022 American Society of Clinical Oncology (ASCO) annual meeting, held in Chicago June 3–7, highlighted important advances in hematologic cancer research. Here, Associate Editor Dr. Michael E. Williams reviews key trials. Meeting abstracts can be viewed in the ASCO meeting library.
The phase 3, multicenter, industry-funded SHINE trial tested the addition of the Bruton tyrosine kinase inhibitor ibrutinib to standard chemoimmunotherapy in older adults with previously untreated mantle cell lymphoma (abstract LBA7502). A total of 523 patients aged 65 and older who were not candidates for autologous stem-cell transplantation consolidation were randomized to receive ei…